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Background: Serum procalcitonin levels have been used as a biomarker of invasive bacterial 
infection and recently have been advocated to guide antibiotic therapy in patients with chronic 
obstructive pulmonary disease (COPD). However, rigorous studies correlating procalcitonin 
levels with microbiologic data are lacking. Acute exacerbations of COPD (AECOPD) have been 
linked to viral and bacterial infection as well as noninfectious causes. Therefore, we evaluated 
procalcitonin as a predictor of viral versus bacterial infection in patients hospitalized with 
AECOPD with and without evidence of pneumonia.
Methods: Adults hospitalized during the winter with symptoms consistent with AECOPD 
underwent extensive testing for viral, bacterial, and atypical pathogens. Serum procalcitonin 
levels were measured on day 1 (admission), day 2, and at one month. Clinical and laboratory 
features of subjects with viral and bacterial diagnoses were compared.
Results: In total, 224 subjects with COPD were admitted for 240 respiratory illnesses. Of 
these, 56 had pneumonia and 184 had AECOPD alone. A microbiologic diagnosis was made in 
76 (56%) of 134 illnesses with reliable bacteriology (26 viral infection, 29 bacterial infection, 
and 21 mixed viral bacterial infection). Mean procalcitonin levels were significantly higher in 
patients with pneumonia compared with AECOPD. However, discrimination between viral 
and bacterial infection using a 0.25 ng/mL threshold for bacterial infection in patients with 
AECOPD was poor.
Conclusion: Procalcitonin is useful in COPD patients for alerting clinicians to invasive bacterial 
infections such as pneumonia but it does not distinguish bacterial from viral and noninfectious 
causes of AECOPD.
Keywords: virus, bacterial infection, procalcitonin, chronic obstructive pulmonary disease, 
bronchitis
Introduction
Guidelines from the Global Initiative for Chronic Obstructive Pulmonary Disease 
(GOLD) recommend antibiotics for the treatment of moderate to severe acute exacer-
bations of chronic obstructive pulmonary disease (AECOPD).1 Several meta-analyses 
support these recommendations to reduce mortality and treatment failures.2 Although 
purulent sputum and growth of a bacterial pathogen suggest infection, definitive cau-
sality with an AECOPD is difficult because patients may be chronically colonized.3,4 
In addition, recent studies using molecular diagnostics indicate that a substantial 
proportion of AECOPD are associated with viral infection.5,6 Accurate methods to 
differentiate viral and bacterial respiratory infections to allow targeted antibiotic 
therapy would be beneficial. Measurement of serum procalcitonin has been proposed 
to discriminate bacterial infection from viral or noninfectious causes.7
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Procalcitonin is a calcitonin precursor that is normally 
produced in neuroendocrine cells of the thyroid and lungs. 
However, in response to bacterial infections, procalcitonin 
is produced by cells throughout the body.8,9 Stimuli of 
  procalcitonin include bacterial products, including endotoxin 
and proinflammatory cytokines such as tumor necrosis 
factor alpha, whereas procalcitonin is attenuated by viral-
induced interferon-γ.8,10 Procalcitonin testing has been 
used successfully as a guide to predict serious bacterial 
infections and medical outcomes in patients with sepsis.11,12 
Recently, procalcitonin has been assessed as a guide to 
antibiotic therapy in patients with respiratory illnesses, 
including COPD.7,13–18 However, microbiologic assessment 
to prove the presence or absence of bacterial infection was 
not performed in the majority of subjects in most trials, 
which is a concern for the Food and Drug Administration 
and Infectious Disease Society of America, as noted in a 
recent workshop.19   Therefore, we examined the utility of 
serum procalcitonin levels as predictors of viral and bacterial 
infection in patients hospitalized with AECOPD using 
rigorous viral and bacteriologic studies.
Methods
Patient population
The study was performed at Rochester General Hospital, 
a 520-bed general medical-surgical hospital located in 
  Rochester (Monroe County), NY. Subjects were participating 
in a larger ongoing study of the relationship between procal-
citonin level and definitive bacterial and viral diagnosis (to 
be described in a separate publication). Adults $21 years 
of age admitted through the Emergency Department to 
Rochester General Hospital with an admitting diagnosis 
compatible with acute respiratory tract infection were 
recruited from November 1 to May 30 during 2008–2009 
and 2009–2010. A subset of subjects with a past medical 
history of COPD and smoking and symptoms consistent with 
AECOPD according to the GOLD criteria (increased   dyspnea, 
cough, and/or increased sputum volume or   purulence) were 
identified for the present analysis.   Confirmation of COPD 
was sought as available in the hospital medical records. 
Patients were screened within 24 hours of admission and 
those given antibiotics prior to admission, or who had 
immunosuppression, cavitating lung disease, or witnessed 
aspiration were excluded.20 In addition, subjects with other 
conditions known to increase serum procalcitonin levels 
(burns, trauma, pancreatitis, renal failure, thyroid tumors) 
were excluded from the study. Subjects or legal guardians 
provided written informed consent. The study was approved 
by the University of Rochester and Rochester General 
  Hospital institutional review boards.
Illness evaluation
At enrollment, demographic, clinical, and laboratory 
information was collected. Chest radiographs were classi-
fied by a pulmonary specialist as infiltrate or no infiltrate. 
Testing for bacterial pathogens included: blood cultures, 
sputum culture, and Gram stain; nose and throat swabs for 
Mycoplasma pneumoniae and Chlamydophila pneumoniae 
polymerase chain reaction; and urine for Streptococcus 
pneumoniae antigen and pneumococcal serology. Sputum 
was induced with normal saline if subjects were unable to 
expectorate an adequate sputum sample spontaneously. 
Specimens were considered adequate by standard criteria 
of .25 polymorphonuclear leukocytes and ,10 epithelial 
cells per high power field. Nose and throat swabs and sputum 
were tested for viruses by reverse transcriptase polymerase 
chain reaction. Sera were collected on hospital day 1 (prior 
to antibiotics) and 4–6 weeks later for viral serology, pneu-
mococcal serology, and procalcitonin measurements. Serum 
was also collected on hospital days 2 and 28 for procalcitonin 
measurement.
Laboratory methods
Standard microbiological testing including blood cultures, 
sputum Gram stain and culture, influenza antigen testing, 
and viral cultures were performed by the Rochester General 
Hospital clinical laboratory. Sputum samples were plated on 
blood, chocolate, and MacConkey agar. Legionella testing 
was performed at the discretion of the treating physician. 
Pneumococcal surface protein A antigens covering families 
1 and 2, obtained from the University of Alabama Bacterial 
Respiratory Pathogen Reference Laboratory, were used in 
an enzyme immunoassay.21 A $4-fold rise in titer was con-
sidered evidence of infection. Urine samples were assayed 
for pneumococcal antigen using BinaxNOW® (Binax Inc, 
Scarborough, ME) urine assay.22
Procalcitonin
Procalcitonin was measured by resolved amplified cryptate 
emission technology (Kryptor PCT, Brahms, Henningsdorf, 
Germany). Functional sensitivity is 0.06 ng/mL (normal 
0.033 ± 0.003 ng/mL).12,23,24 Immunoglobulin G titers in 
acute and convalescent serum for each virus was deter-
mined using established EIA methods.25 A $4-fold rise in 
viral specific immunoglobulin G was considered evidence 
of infection.
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Real-time polymerase chain reaction
Assays for respiratory syncytial virus, human metapneumo-
virus, M. pneumoniae, and C. pneumoniae used published 
methods.25–27 Primers and probes for other viruses were as 
  follows: influenza A (matrix gene), influenza B (nonstructural 
1 [NS1] gene), coronaviruses (polymerase gene), and 
parainfluenza viruses (nucleocapsid gene). Sequences can be 
supplied on request. Bacteriology was considered unreliable 
if sputum was not obtained or was obtained after 6 hours 
of antibiotics, or was of inadequate quality. Subjects were 
not considered to be viral infection alone or no infectious 
  diagnosis unless “reliable” bacteriology was negative.
Statistical analysis
Fisher’s Exact and t-tests were used to compare distributions 
of categorical and continuous clinical variables for pneumonia 
versus AECOPD patients. Differences in procalcitonin levels 
were evaluated using the Wilcoxon test, summarized using 
both means and standard deviations and medians with inter-
quartile range, and receiver operator curves were plotted and 
area under the curve tabulated. Multiple logistic regression was 
used to model maximum (procalcitonin over days 1–2) $0.25 
as a function of clinical covariates. SAS 9.2 was used for all 
analyses, with tests performed at the two-sided 0.05 level.
Results
Enrollment and microbiology
During two winters from 2008 to 2010, we enrolled 532 subjects, 
of whom 224 had a history of COPD and a respiratory illness 
with symptoms of AECOPD. Of these 224 subjects, 213 had 
a single illness, 12 had two, and one subject had three hospi-
talizations for a total of 240 illnesses evaluated. The average 
time between AECOPD admissions for subjects with more than 
one illness evaluation was 7 ± 4 months. A diagnosis of COPD 
was confirmed by pulmonary function testing, pulmonary phy-
sician evaluation, or radiographic changes in 90% of subjects. 
Chest radiographs on admission revealed pneumonia in 56 cases, 
and 184 illnesses were considered to be AECOPD alone 
(Figure 1). Bacteriology was considered reliable in 134 (56%) 
of the 240 illnesses (104 AECOPD and 30 pneumonia).   Notably, 
47 viral infections alone (37 AECOPD and 10 pneumonia) 
were excluded from further analyses of microbiology, primar-
ily because sputum samples were collected more than 6 hours 
after antibiotics had been started. No patient was bacteremic. 
A variety of viral pathogens were identified and 45% were 
associated with bacterial infection (Table 1). S. pneumoniae 
(22 cases) was the most common bacterial organism identified 
and was associated with viral infection in 13 (59%) and mixed 
bacterial infection in three (14%). Of the 22 subjects with 
  pneumococcal infection, half had more than one positive test 
(ie, sputum culture, pneumococcal serology, or urine antigen). 
Of the 31 subjects considered to have bacterial infection based 
on sputum culture alone, all had 3–4+ growth of a potential 
pathogen and 87% had a consistent Gram stain.
Pneumonia procalcitonin analysis
Procalcitonin values were measured on day 1 (admission), 
day 2, and at one month convalescence. Mean   procalcitonin 
None
43
V
37
None
47
B
16
BV
16
Bacteriology  Bacteriology 
Illnesses in subjects with COPD
240 
AECOPD
184
Reliable
104
Not reliable
80 
Not reliable
26 
Reliable
30
V
25
V
10
B
13
None
16
None
11
V
1
BV
5
Pneumonia
56
Figure 1 Flow chart of patient groups. Bacteriology is divided into reliable and not reliable.
Abbreviations: V, viral alone; B, bacterial alone; BV, bacterial + viral; none, no microbiologic diagnosis; COPD, chronic obstructive pulmonary disease.
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values were higher in COPD patients with pneumonia 
compared with those with AECOPD only (Table 2). 
Procalcitonin values decreased significantly in both 
groups at the convalescent time point. Using published 
procalcitonin thresholds of $0.25 ng/mL as indicative of 
possible, and $0.5 ng/mL as probable bacterial infection, 
59% of pneumonia patients would have been classified 
as possible and 48% as probable bacterial infection using 
the maximum procalcitonin on either the day 1 or day 2 
measurement.15,16
AECOPD procalcitonin analysis
Clinical features
Because empiric antibiotics are recommended for all patients 
with pneumonia, further analyses were restricted to those with 
AECOPD only. In contrast with subjects with radiographic 
evidence of pneumonia, only 31 of 184 (17%) in the AECOPD 
group had procalcitonin values $0.25 ng/mL. Clinical fea-
tures associated with a   procalcitonin value , or $0.25 ng/mL 
in the AECOPD group are shown in Table 3. Patients with 
elevated procalcitonin values more often received inhaled or 
oral steroids, had higher white blood cell levels, temperature, 
intensive care unit admission rates, and CURB-65 scores.   
Of note, the frequency of subjects having the three cardinal 
symptoms warranting antibiotics, as defined by Anthonisen 
criteria (increased dyspnea, sputum volume, sputum 
purulence), were similar in the two groups, as were the rates 
of documented bacterial infections. Clinical features were 
evaluated by logistic regression [odds ratio (OR), 95% con-
fidence interval (CI)] and elevated white blood cells (OR 1.2 
[95% CI 1.1–1.3], P = 0.0004), temperature (OR 1.9 [95% 
CI 1.2–3.0], P = 0.01). and ICU admission (OR 3.9 [95% CI 
1.3–3.0], P = 0.01) remained significant associations.
Microbiology
Clinical features were not significantly different for AECOPD 
due to viral infection alone compared with those with bacte-
rial infection alone or mixed viral bacterial infection with the 
exception of greater inhaled corticosteroid use in the bacte-
rial infection alone + mixed viral bacterial infection group 
(data not shown). Maximum procalcitonin values on day 
1 or 2 in patients with bacterial infection (bacterial infection 
Table 2 Procalcitonin values (ng/mL) of subjects with pneumonia compared with those with acute exacerbations of chronic obstructive 
pulmonary disease
Study group and day Mean ± SD 
ProCT ng/mL
Median (IQR) 
ProCT ng/mL
Wilcoxon exact test AUC (95% CI)
Hospital day 1 (admission)
  Pneumonia (n = 56) 3.62 ± 17.38 0.31 (1.29) P , 0.0001 0.76 (0.68–0.84)
  AECOPD (n = 181) 0.39 ± 2.22 0.08 (0.07)
Hospital day 2
  Pneumonia (n = 54) 3.30 ± 10.32 0.33 (0.69) P , 0.0001 0.75 (0.67–0.82)
  AECOPD (n = 172) 0.49 ± 2.26 0.09 (0.09)
Maximum on day 1 or 2
  Pneumonia (n = 56) 4.73 ± 17.92 0.39 (2.33) P , 0.0001 0.75 (0.67–0.83)
  AECOPD (n = 184) 0.52 ± 2.31 0.09 (0.01)
Days 28–42
  Pneumonia (n = 46) 0.22 ± 0.47 0.07 (0.09) P = 0.22 0.56 (0.46–0.66)
  AECOPD (n = 153) 0.12 ± 0.33 0.06 (0.06)
Abbreviations:  AECOPD,  acute  exacerbations  of  chronic  obstructive  pulmonary  disease;  AUC,  area  under  the  concentration-time  curve;  CI,  confidence  interval;   
IQR, interquartile range; ProCT, procalcitonin.
Table 1 Microbiology in subjects with reliable bacteriology
Organism AECOPD 
n = 104
Pneumonia 
n = 30
Single organism infections
  Influenza A 5 0
  Influenza B 0 0
  Respiratory syncytial virus 7 0
  Human metapneumovirus 1 0
  Parainfluenza viruses (1–3) 3 0
  Coronaviruses (229E and OC43) 8 1
  Streptococcus pneumoniae 2 4
  Haemophilus influenzae 4 1
  Moraxella catarrhalis 1 1
  Staphylococcus aureus 1 3
  Gram-negative rods 4 2
  Mycoplasma pneumoniae 0 2
  Chlamydophila pneumoniae 0 0
Multiple pathogen infections
  Mixed viral 1 0
  Viral + S. pneumoniae 9 3
  Viral + other bacteria 7 2
  S. pneumoniae + other bacteria 4 0
  Mixed other bacteria 0 0
Abbreviation: AECOPD, acute exacerbations of chronic obstructive pulmonary 
disease.
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alone + mixed viral bacterial infection) were compared with 
those without bacterial infection (viral infection alone + no 
pathogen identified) and were not significantly different 
(Table 4, analysis A). Because procalcitonin is thought to be 
attenuated by virally induced interferon, procalcitonin values 
were compared for those having bacterial infection alone 
with those having both bacterial and viral infection (Table 4, 
analysis B). Procalcitonin values were slightly higher in 
the mixed viral bacterial infection group compared with the 
bacterial infection alone group, indicating that the presence 
of concomitant viral infection does not significantly attenuate 
the procalcitonin response in patients with dual infections. 
Furthermore, among patients with known viral infection (viral 
infection alone or mixed viral bacterial infection, Table 4, 
analysis C), procalcitonin values were significantly higher 
in the mixed viral bacterial infection group. Given the lack 
of difference noted in analysis A, this finding might suggest 
that the presence of a viral infection is necessary for inva-
sive bacterial infection. Using the $0.25 ng/mL threshold, 
the specificity for bacterial infection among patients with a 
documented viral infection was 96% but sensitivity was low 
at 31%, with a positive predictive value of 83% and negative 
predictive value of 69% (Figure 2). Although a significant 
difference in the mean and median procalcitonin values in this 
group could be demonstrated, discrimination between viral 
and bacterial coinfection by procalcitonin was poor (Figure 3). 
Although only one of 25 patients with virus infection alone 
would have been misclassified as possible bacterial infection, 
Table 3 Clinical characteristics of subjects with nonpneumonic acute exacerbations of chronic obstructive pulmonary disease stratified 
by procalcitonin values above and below 0.25 ng/mL
ProCT , 0.25 ng/mL 
n = 153
ProCT $ 0.25 ng/mL 
n = 31
P value
Age (mean ± SD) 66.3 ± 12.3 68.8 ± 14.2 0.31
Male (%) 83 (54) 14 (45) 0.43
Race, white 131 (86) 29 (90) 0.58
Diabetes 52 (34) 11 (35) 1.0
Congestive heart failure 47 (31) 13 (42) 0.29
Influenza vaccine 108 (71) 24 (74) 0.52
Pneumococcal vaccine 144 (94) 30 (97) 1.0
Chronic oral steroid use 25 (16) 11 (35) 0.02
Chronic inhaled steroid use 83 (54) 24 (77) 0.02
Home oxygen use 63 (41) 17 (55) 0.17
Symptoms (%)
  Upper respiratory tract infection 116 (76) 20 (65) 0.26
  Cough 144 (94) 29 (94) 0.44
  Sputum production* 120 (78) 26 (84) 0.62
  Purulent sputum* 91 (59) 18 (58) 1.0
  Dyspnea* 148 (97) 30 (97) 1.0
  Three Anthonisen criteria present 87 (57) 17 (55) 0.85
  Rigors 35 (23) 6 (19) 0.48
Physical examination (%)
  Wheezing 123 (80) 23 (74) 0.48
  Rales 36 (24) 11 (35) 0.18
  Rhonchi 43 (28) 8 (26) 1.0
  Diaphoresis 14 (9) 7 (23) 0.06
  Temperature (mean ± SD) 36.9 ± 0.7 37.3 ± 1.2 0.01
  Respiratory rate (mean ± SD) 26 ± 6 27 ± 10 0.17
  Oxygen saturation (mean ± SD) 91.7 ± 6 92.8 ± 5.1 0.31
White blood cells × 103/mL (mean ± SD) 10.4 ± 3.9 14.2 ± 6.4 0.0001
  % neutrophils (mean ± SD) 72 ± 13 75 ± 16 0.16
  % band forms (mean ± SD) 1.5 ± 2.4 2.8 ± 3.7 0.01
CURB-65 score 1.6 ± 1.0 2.3 ± 1.0 0.0002
Bacterial infection documented 24 (16) 8 (26) 0.20
Intensive care 12 (8) 8 (26) 0.008
Length of stay 7 ± 32 8 ± 9 0.93
Death 3 (2) 1 (3) 0.52
Note: *Anthonisen criteria.
Abbreviations: SD, standard deviation; ProCT, procalcitonin.
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11 of 16 patients (69%) with concomitant bacterial infection 
would have been categorized as low risk of bacterial infection. 
Interestingly, the single patient with a viral infection alone 
and elevated procalcitonin levels had influenza complicated 
by pericardial tamponade, necessitating surgical intervention 
on the second hospital day. As demonstrated in Figure 3, most 
subjects in any category (viral alone, viral + bacterial, or 
bacterial alone) fell below the 0.25 ng/mL threshold on day 
1 or 2 of hospitalization.
Discussion
Infection is a major cause of morbidity and mortality among 
patients with COPD.28 In COPD patients presenting to the 
hospital with dyspnea, our study demonstrates a wide variety 
of viral and bacterial pathogens, as well as a high incidence 
of pneumonia. Recently, use of procalcitonin to guide clinical 
decisions has been shown to reduce antibiotic use significantly 
in patients with respiratory illnesses without compromising 
composite patient outcomes in a number of randomized 
interventional trials.13–18,29 Although procalcitonin-guided 
decisions have been promulgated as a method to “rule out” 
bacterial infection, the 0.25 ng/mL threshold for recommend-
ing antibiotic treatment is not based on microbiologic data. 
Recovery without antibiotics or with an abbreviated course 
has been equated with the absence of a bacterial infection. 
The lack of microbiologic correlation with procalcitonin 
levels is likely to slow endorsement of procalcitonin-guided 
management in respiratory illness.19,30,31
Ours is the first study in the US to examine the utility of 
procalcitonin levels in patients with COPD, and consistent 
with the European literature, we found that a high procal-
citonin level was relatively specific for invasive bacterial 
disease such as pneumonia.32,33 In addition, elevated procal-
citonin values in the AECOPD group correlated with higher 
temperature, white blood cells, and more severe illness, 
suggesting the possibility of occult pneumonia. Thus, high 
procalcitonin values may alert clinicians to the presence of 
bacterial pneumonia when the chest radiograph results are 
negative or ambiguous.
However, our results also indicate that minor elevations at 
the low end of the procalcitonin spectrum do not   correlate with 
bacterial infection for subjects with AECOPD alone. It has 
been estimated that approximately 40%–50% of AECOPD 
cases are due to bacterial infections.34 The precise contribu-
tion of bacterial infection is difficult to define because the 
Table 4 Maximum day 1 or 2 serum ProCT values in subjects with acute exacerbations of chronic obstructive pulmonary disease and 
reliable bacteriology
Analysis Groups Mean ± SD 
ProCT ng/mL
Median (IQR) 
ProCT ng/mL
Wilcoxon exact  
test
AUC (95% CI)
A Any bacterial 
n = 32
0.32 ± 0.57 0.10 (0.17) P = 0.06 0.62 (0.49–0.74)
Nonbacterial  
n = 72
0.20 ± 0.66 0.08 (0.06)
B Bacterial alone 
n = 16
0.17 ± 0.21 0.09 (0.09) P = 0.06 0.70 (0.51–0.88)
Bacterial + virus 
n = 16
0.46 ± 0.76 0.14 (0.25)
C Bacterial + virus 
n = 16
0.46 ± 0.76 0.14 (0.25) P = 0.03 0.70 (0.53–0.87)
Virus alone 
n = 25
0.11 ± 0.07 0.09 (0.07)
Abbreviations: AUC, area under the concentration-time curve; CI, confidence interval; IQR, interquartile range; ProCT, procalcitonin.
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Figure 2 Receiver operator curve for procalcitonin as a diagnostic tool for bacterial 
infection in patients with a documented viral infection and acute exacerbations of 
chronic obstructive pulmonary disease without pneumonia. Specificity is indicated 
on y-axis and sensitivity on x-axis.
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airways of COPD patients may be chronically colonized.3,4 
Acquisition of new strains of Haemophilus   influenzae and 
Moraxella catarrhalis, rather than bacterial load, appears 
to be the most important factor in the pathogenesis of acute 
exacerbations.35 This factor has not been accounted for in 
AECOPD antibiotic trials and might explain the modest 
beneficial effects of antimicrobial treatments observed.
We accept that some subjects who were classified as 
having bacterial infection in our study were colonized 
rather than infected. However, only 17% of patients overall 
with AECOPD and without pneumonia, and only 25% of 
those with evidence of bacterial infection had procalcitonin 
levels $0.25 ng/mL. While it is possible that this small 
subgroup represents those who will actually benefit from 
antibiotic treatment, such a conclusion is premature.   Notably, 
of those with procalcitonin levels ,0.25 ng/mL, 57% had 
three Anthonisen criteria, suggesting they would benefit 
from antibiotic treatment based on past studies.36 Thus, only 
two conclusions are possible, ie, either the contribution of 
bacterial infection in AECOPD has been markedly overesti-
mated or procalcitonin values do not differentiate bacterial 
bronchitis from viral or noninfectious etiologies.
Our study adds to the growing body of literature which 
questions the utility of procalcitonin levels to discriminate 
viral-associated from bacterial-associated AECOPD. In a 
study by Daniels et al, procalcitonin levels were measured in 
outpatients enrolled in a trial of doxycycline for AECOPD.37 
A significant benefit of doxycycline was noted for patients 
with procalcitonin levels ,0.1 ng/mL. In this study, as well as 
in two additional reports, no differences in procalcitonin lev-
els were noted in patients with or without bacteria in   sputum 
during exacerbation.32,37,38 Our study provides the most 
  rigorous microbiologic analysis of moderate to severe illness 
requiring hospitalization to date, particularly for subjects who 
were deemed negative for bacterial infection. Unlike prior 
  studies, we did not consider patients to be free of bacterial 
infection unless adequate samples were taken in a timely 
fashion and without antibiotic use prior to hospitalization.
Our study had several limitations. The number of patients 
with documented bacterial infection was relatively small. 
However, large numbers of subjects are not needed to show 
that a test is insensitive, especially if missing even a few 
patients with potentially treatable bacterial infections is 
considered unacceptable. Because medical information was 
restricted to that available in the hospital medical record, we 
could not classify the stage of COPD using GOLD criteria 
in our subjects. Lastly, we did not test for rhinovirus, a com-
mon pathogen in this population, although this omission does 
not invalidate the findings for those patients with a viral or 
bacterial infection identified.
In conclusion, we found that elevated serum procalcitonin 
levels are associated with more severe illness in patients 
hospitalized with symptoms of AECOPD and that high 
values may alert clinicians to the possibility of pneumonia. 
However, low procalcitonin values do not “rule out” bacterial 
infection in AECOPD. Before procalcitonin-based treatment 
algorithms are endorsed, additional studies in COPD patients 
should be performed. Clinical trials focusing on antibiotic 
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Figure 3 Procalcitonin values in subjects with acute exacerbations of chronic obstructive pulmonary disease without pneumonia. Individual procalcitonin values expressed as 
ng/mL on a log 10 scale. Viral alone patients are shown on admission (V1), day 2 (V2), and day 28 (V3) and bacterial + viral are shown on admission (BV1), day 2 (BV2), and 
day 28 (BV3) and bacterial alone on admission (B1), day 2 (B2), and day 28 (B3). The 0.25 ng/mL and 0.50 ng/mL procalcitonin levels are indicated by the dotted lines.
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benefit are needed specifically in patients with nonpneumonic 
exacerbations associated with low procalcitonin values.
Acknowledgments
The authors wish to thank Jamie Biear, Karen   Leavenworth, 
and Kyle Quinn for their technical support, Susan   Romansky, 
Tashara Smalls, and the staff of the Rochester General 
  Hospital clinical microbiology, hematology and   chemistry 
laboratory for assistance with specimen retrieval, and mem-
bers of the respiratory therapy department for help with 
sputum induction. This work was supported by the National 
Institute Health at the National Institute of Allergy and 
Infectious Diseases (1R01AI079446-01).
Disclosures
Dr Falsey has served as a consultant for sanofipasteur, 
GSK Biologics, Medimmune, AstraZeneca, and Novartis. 
Dr Walsh has served as a consultant for Novartis, Alnylam, 
AstraZeneca, Medimmune, and Boehringer Ingelheim. 
Otherwise, the authors have no financial conflicts of interest 
which could potentially bias the results of the study.
References
1.  Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD 
Scientific Committee. Global strategy for the diagnosis, management, 
and prevention of chronic obstructive pulmonary disease. NHLBI/
WHO global initiative for chronic obstructive lung disease (GOLD) 
workshop summary. Am J Respir Crit Care Med. 2001;163(5): 
1256–1276.
2.  Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, 
Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmo-
nary disease. Cochrane Database Syst Rev. 2006;2:CD004403.
3.  Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstruc-
tive pulmonary disease. A study of stable and exacerbated outpatients 
using the protected specimen brush. Am J Respir Crit Care Med. 1995; 
152(4 Pt 1):1316–1320.
4.  Martinez FJ. Pathogen-directed therapy in acute exacerbations 
of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 
2007;4(8):647–658.
5.  Kherad O, Rutschmann OT. Viral infections as a cause of chronic 
obstructive pulmonary disease (COPD) exacerbation. Praxis (Bern 1994). 
2010;99(4):235–240. German.
6.  De Serres G, Lampron N, La Forge J, et al. Importance of viral and bacte-
rial infections in chronic obstructive pulmonary disease exacerbations. 
J Clin Virol. 2009;46(2):129–133.
7.  Fowler CL. Procalcitonin for triage of patients with respiratory tract 
symptoms: A case study in the trial design process for approval of a 
new diagnostic test for lower respiratory tract infections. Clin Infect Dis. 
2011;52(4):S351.
8.  Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical 
review 167: Procalcitonin and the calcitonin gene family of pep-
tides in inflammation, infection, and sepsis: A journey from calci-
tonin back to its precursors. J Clin Endocrinol Metab. 2004;89(4): 
1512–1525.
9.  Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. 
Ubiquitous expression of the calcitonin-i gene in multiple tissues in 
response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.
  10.  Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin 
with C-reactive protein, interleukin 6 and interferon-alpha for dif-
ferentiation of bacterial vs viral infections. Pediatr Infect Dis J. 
1999;18(10):875–881.
  11.  Nylen ES, Snider RH Jr, Thompson KA, Rohatgi P, Becker KL. 
Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 
1996;312(1):12–18.
  12.  Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic 
inflammation: A harmful biomarker and a therapeutic target. Br J 
Pharmacol. 2010;159(2):253–264.
  13.  Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of 
antibiotic therapy in community-acquired pneumonia: A randomized 
trial. Am J Respir Crit Care Med. 2006;174(1):84–93.
  14.  Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of 
  procalcitonin-guided treatment on antibiotic use and outcome in lower 
respiratory tract infections: Cluster-randomised, single-blinded inter-
vention trial. Lancet. 2004;363(9409):600–607.
  15.  Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of 
exacerbations of COPD: A randomized, controlled trial comparing 
  procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9–19.
  16.  Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-
based guidelines vs standard guidelines on antibiotic use in lower 
respiratory tract infections: The ProHOSP randomized controlled trial. 
JAMA. 2009;302(10):1059–1066.
  17.  Kristoffersen KB, Sogaard OS, Wejse C, et al. Antibiotic treatment 
interruption of suspected lower respiratory tract infections based on a 
single procalcitonin measurement at hospital admission – a randomized 
trial. Clin Microbiol Infect. 2009;15(5):481–487.
  18.  Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use 
vs a standard approach for acute respiratory tract infections in primary 
care. Arch Intern Med. 2008;168(18):2000–2007.
  19.  Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. 
Clin Infect Dis. 2011;52(4):S362.
  20.  Alscher DM, Mettang T. Procalcitonin in peritoneal dialysis – a useful 
marker of inflammation? Perit Dial Int. 2005;25(5):441–444.
  21.  Nahm MH. Bacterial respiratory pathogen reference laboratory.   
Available from: http://www.vaccine.uab.edu/. Accessed May 11, 2007.
  22.  Diederen BM, Peeters MF. Rapid diagnosis of pneumococcal pneumo-
nia in adults using the binax NOW streptococcus pneumoniae urinary 
antigen test. Int J Infect Dis. 2007;11(3):284–285.
  23.  Maniaci V, Dauber A, Weiss S, Nylen E, Becker KL, Bachur R.   
Procalcitonin in young febrile infants for the detection of serious bacte-
rial infections. Pediatrics. 2008;122(4):701–710.
  24.  Nylen E, Muller B, Becker KL, Snider R. The future diagnostic role 
of procalcitonin levels: The need for improved sensitivity. Clin Infect 
Dis. 2003;36(6):823–824.
  25.  Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus 
infections in young and elderly adults. J Infect Dis. 2003;187(5): 
785–790.
  26.  Falsey AR, Formica MA, Treanor JJ, Walsh EE. Comparison of 
quantitative reverse transcription-PCR to viral culture for assess-
ment of respiratory syncytial virus shedding. J Clin Microbiol. 
2003;41(9):4160–4165.
  27.  Gullsby K, Storm M, Bondeson K. Simultaneous detection of 
Chlamydophila pneumoniae and Mycoplasma pneumoniae by use 
of molecular beacons in a duplex real-time PCR. J Clin Microbiol. 
2008;46(2):727–731.
  28.  Sethi S, Murphy TF. Infection in the pathogenesis and course 
of chronic obstructive pulmonary disease. N Engl J Med. 
2008;359(22):2355–2365.
  29.  Schuetz P, Chiappa V , Briel M, Greenwald JL. Procalcitonin algorithms 
for antibiotic therapy decisions: A systematic review of randomized 
controlled trials and recommendations for clinical algorithms. Arch 
Intern Med. 2011;171(15):1322–1331.
  30.  Martinez FJ, Curtis JL. Procalcitonin-guided antibiotic therapy in COPD 
exacerbations: closer but not quite there. Chest. 2007;131(1):1–2.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
134
Falsey et alInternational Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2012:7
  31.  Food and Drug Administration and Infectious Disease Society of 
America. FDA-IDSA public workshop: Advancing clinical devel-
opment of molecular and other diagnostic tests for respiratory tract 
infections, November 12–13, 2009. Available from: http://www.fda.
gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm181140.
htm. Accessed May 16, 2011.
  32.  Lacoma A, Prat C, Andreo F, et al. Value of procalcitonin, C-reactive 
protein, and neopterin in exacerbations of chronic obstructive pulmo-
nary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:157–169.
  33.  Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive pro-
tein in hospitalized adult patients with community-acquired pneumonia 
or exacerbation of asthma or COPD. Chest. 2011;139(6):1410–1418.
  34.  Murphy TF, Sethi S, Niederman MS. The role of bacteria in exacerba-
tions of COPD. A constructive view. Chest. 2000;118(1):204–209.
  35.  Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and 
exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 
2002;347(7):465–471.
  36.  Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, 
Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive 
pulmonary disease. Ann Intern Med. 1987;106(2):196–204.
  37.  Daniels JM, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive 
protein as predictive markers of response to antibiotic therapy in acute 
exacerbations of COPD. Chest. 2010;138(5):1108–1115.
  38.  Kherad O, Kaiser L, Bridevaux PO, et al. Upper-respiratory viral 
infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4): 
896–904.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
135
Serum procalcitonin in acute exacerbation of COPD